General Information
Cerevel Schizophrenia 2001
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 in Participants with Schizophrenia Experiencing an Acute Exabercation of Psychosis
| Protocol | CVL-231-2001 |
|---|---|
| Identifier | |
| UID | c23dd048-dcf1-43a2-bfb2-9fdadc8ebb0b |
| Status | Done - Archived |
| Phase | 2 |
| Category | Schizophrenia / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2022-05-24 11:15 |
| Last Updated | 2025-01-07 15:38 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2024-05-07 | No |
| Enrollment Open | 2022-10-05 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-08-17 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-12-04 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Volk, Stephen | SVolk | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Cereval Therapeutics |
|---|---|
| Division | Cereval |
| Team | Cereval |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | PPD Investigator Services, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
